Back to News
Market Impact: 0.32
2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio's FUCASO Reveals That In Vivo Durable Persistence of CAR-T cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression
Source: PR Newswire
Healthcare & BiotechCompany Fundamentals
IASO Bio presented an updated retrospective analysis of 102 patients from the pivotal FUMANBA-1 study of equecabtagene autoleucel (Fucaso) at the 2026 IMS meeting. The data showed durable in vivo CAR-T-cell persistence associated with sustained minimal residual disease (MRD) negativity and delayed disease progression, supporting the therapy's long-term efficacy profile.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
More News
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- ‘U.S. trade policy is damaging the U.S. auto industry’: Canada’s purchase of American cars hits new low as Trump’s tariffs backfire on U.S. automakers
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
- Beware borrowing costs: The jump in yields could hit these debt-laden stocks the most
- Why Akamai Stock Is Up Today
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Hebbia Alternatives: A Workflow-Based Buyer’s Guide
- 2026 Global Markets Outlook: Asset Allocation After the Great Disconnect